Skip to main content
letter
. 2020 Jul 3;34(10):2805–2808. doi: 10.1038/s41375-020-0953-3

Fig. 2.

Fig. 2

Management of COVID-19 screening before (a) or during (b) ruxolitinib and management of ruxolitinib in case of mild (c) or moderate (d) COVID-19 infection. Mild infection: respiratory symptoms not requiring hospitalization. Moderate infection: hypoxia (SPO2 ≤94%) requiring ventilatory support but not mechanical ventilation.